Medicare Price Negotiation, Generic Availability, and Out-of-Pocket Costs for Cardiac Medications - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medicare Drug Price Negotiations, Generic Access, and Patient Costs for Cardiovascular Medications

  • By

  • Celeste W. Franklin

  • Nathalia Ladino

  • Neha Parvathala

  • Gary C. N. Hettinger

  • Harmony R. Reynolds

  • Samrachana Adhikari

  • Saul Blecker

  • Amrita Mukhopadhyay

  • November 19, 2026

Share

Clinical Scorecard: Medicare Drug Price Negotiations, Generic Access, and Patient Costs for Cardiovascular Medications

At a Glance

CategoryDetail
ConditionMedicare plan-level out-of-pocket costs for selected cardiovascular medications
Key MechanismsA plan-level difference-in-differences analysis compared 30-day out-of-pocket costs before and after implementation of Medicare price negotiation, separately for medications with and without generic alternatives; estimates are associations.
Target PopulationMedicare drug coverage plans covering selected anticoagulants, SGLT2 inhibitors, ARNI, PCSK9 inhibitors, or ticagrelor; no beneficiary-level data were analyzed.
Care SettingMedicare prescription drug coverage, including Medicare Advantage and Stand-Alone plans

Key Highlights

  • The repeated cross-sectional analysis included 6,215 Medicare drug coverage plans.
  • For medications without a generic option, price negotiation was associated with a $56.63 decrease in 30-day out-of-pocket costs (95% CI, $55.48 to $57.78).
  • For medications for which a generic became available, the associated decrease was $7.46 (95% CI, $6.05 to $8.78).
  • Costs were calculated for specified starting regimens during the initial coverage phase.
  • The study covered the first year after implementation and did not assess beneficiary-level costs or clinical outcomes.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • The article cites prior literature associating high out-of-pocket medication costs with poorer adherence and outcomes; this study did not assess adherence or clinical outcomes.
        • The analysis did not include beneficiary-level enrollment, diagnoses, or other cost barriers.

        Patient & Prescribing Data

        No individual beneficiaries were studied; the analysis used publicly accessible plan-level data from 6,215 Medicare drug coverage plans.

        Thirty-day out-of-pocket costs were calculated for specified starting regimens. The reported association with lower costs was larger for medications without a generic option than for medications for which a generic became available.

        Clinical Best Practices

        • The estimates are plan-level associations from a difference-in-differences analysis, not beneficiary-level cost or clinical outcome estimates.
        • The study was limited to the first year after implementation, selected cardiovascular medications, and 30-day costs during the initial coverage phase.
        • The authors identified the timing of generic entry relative to Medicare negotiation as a potential limitation of the negotiation process.

        Related Resources & Content

        Original Source(s)

        Related Content